O bstructive sleep apnea (OSA) is a common sleep disorder affecting approximately 5% of North American adults. Repeated obstruction of the upper airway during sleep results in sleep fragmentation, excessive daytime sleepiness and diminished quality of life (1, 2) . The gold standard therapy for OSA is continuous positive airway pressure (CPAP), which acts as a pneumatic splint that keeps the airway open during sleep. Untreated OSA increases the risk of all-cause mortality -cardiovascular mortality in particular -and is associated with cardiovascular complications such as hypertension, stroke, arrhythmias, myocardial infarction and heart failure (2-7). The association between stroke and OSA persists even after controlling for common stroke risk factors such as diabetes mellitus, dyslipidemia, smoking and hypertension (8) , suggesting that OSA is an independent risk factor for stroke (9) . Although the strong association between OSA and cardiovascular disease has been well documented, the pathophysiological mechanism that leads to the increased risk remains controversial.
One possible explanation is increased blood coagulability. Individuals with OSA have a complex array of factors that may result in a state of hypercoagulability. Research suggests that hypoxemia experienced by patients during apneas triggers the release of inflammatory factors that alter the micromilieu of the blood, resulting in increased blood coagulability (10) (11) (12) . These factors may, in combination, lead to a hypercoagulable state. In the present review, we examine coagulability as a potential mechanism for the increased incidence of cardiovascular morbidity and mortality observed among patients with OSA, and the factors that contribute to this state.
Factors contributing to hypercoagulablity hematocrit (table 1)
Hematocrit plays an important role in hemostasis because it affects blood viscosity and platelet aggregation. Individuals who experience hypoxic conditions often have increased hematocrit (eg, those living at higher altitudes compensate for lowered arterial oxygen tension through an increased hematocrit) (13) . Several studies have determined that patients with OSA have increased hematocrit levels (14) (15) (16) (17) (18) (19) , and that the increases in hematocrit correlate positively with OSA severity (14) . Only one study (Reinhart et al [20] ) found no differences in hematocrit among CPAP-naive patients, CPAP-treated patients and controls. Both short-term (one night, one month and three months), and long-term (one year) CPAP therapy were found to decrease hematocrit levels (16, 17, 21, 22) and, when examining background: Obstructive sleep apnea (OSA) is a common disorder that affects both quality of life and cardiovascular health. The causal link between OSA and cardiovascular morbidity/mortality remains elusive. One possible explanation is that repeated episodes of nocturnal hypoxia lead to a hypercoagulable state that predisposes patients to thrombotic events. There is evidence supporting a wide array of hematological changes that affect hemostasis (eg, increased hematocrit, blood viscosity, platelet activation, clotting factors and decreased fibrinolytic activity). obJective: To provide a comprehensive review of the current evidence associating OSA with increased coagulability, and to highlight areas for future research. Methods: Keyword searches in Ovid Medline were used to identify relevant articles; all references in the articles were searched for relevant titles. The Web of Science was used to identify articles citing the relevant articles found using the Ovid Medline search. All original peer-reviewed articles, meta-analyses and systematic reviews regarding the pertinent topics between 1990 and present were selected for review. results: Hematocrit, blood viscosity, certain clotting factors, tissue factor, platelet activity and whole blood coagulability are increased in patients with OSA, while fibrinolysis is impaired. conclusion: There is considerable evidence that OSA is associated with a procoagulant state. Several factors are involved in the procoagulant state associated with OSA. There is a need for adequately powered clinical studies involving well-matched control groups to address potential confounding variables, and to accurately delineate the individual factors involved in the procoagulant state associated with OSA and their response to treatment. CPAP-naive and CPAP-treated patients, significant differences were found in their hematocrit levels (23) . Despite statistically significant elevations in hematocrit among untreated patients with OSA, these elevations did not reach the threshold of clinical polycythemia, but resulted in a mean hematocrit of 43.5% in patients with severe OSA (14) . Although an elevated hematocrit would predispose patients to clot formation, no studies have been conducted to elucidate whether a raised, but subpolycythemic, hematocrit level affects cardiovascular outcomes in patients with OSA.
blood viscosity (table 2)
Untreated patients with OSA have increased blood viscosity, which may contribute to slowing of blood flow, stasis, clot formation and vessel occlusion (19, (23) (24) (25) . Thus, hyperviscosity is a potential mechanism for increased coagulability (25, 26) . Dikmenoglu et al (24) reported that the decline in oxygen saturation correlated inversely with morning plasma viscosity in untreated patients with OSA. The cause of the increased viscosity is likely related, at least in part, to raised hematocrit and fibrinogen levels, which can alter blood viscosity independent of cardiovascular risk factors such as hypertension (19, 25) .
In a study examining the effect of CPAP therapy on various blood rheology parameters (20) , plasma viscosity and fibrinogen levels remained elevated in patients with OSA even after six months of CPAP therapy, although compliance was not reported. This finding is controversial because more recently Tazbirek et al (23) found that blood viscosity fell rapidly after initiation of effective CPAP treatment (blood viscosity in untreated patients with OSA was 18.6% higher than in controls, and decreased by 10.5% after only five nights of CPAP treatment). Similarly, the same investigators demonstrated an increase in plasma viscosity among patients with OSA (7.2% versus controls), which decreased by 4.1% after five nights of therapy (23) .
Limitations to the studies examining blood viscosity include small sample sizes and poorly matched controls. Nevertheless, the findings warrant further investigation because they suggest that OSA may be an independent contributor to hyperviscosity, and that the effect is reversible with CPAP treatment.
clotting factors (table 3) Factors Xiia and viia, and thrombin: The clotting factors XIIa (FXIIa) and VIIa (FVIIa), and thrombin are necessary components of the clotting cascade. Increased levels of FXIIa, FVIIa and thrombin-antithrombin (TAT) have been found in patients with OSA (27) . TAT is formed when thrombin is bound by antithrombin III, and is a marker of thrombin turnover, suggesting increased coagulation (28) . TAT levels, specifically, have been found to increase significantly when induced by hypoxic conditions (29) , and FVIIa levels have been shown to decrease by as much as 30% after long-term CPAP therapy (30) . Conversely, Robinson et al (27) found that despite increased levels of these clotting factors in patients with OSA, one month of CPAP therapy (mean [± SD] 5±1.9 h/night) had no effect on post-treatment levels (27) . This may be because the decrease in clotting factors is indirectly caused by a decrease in hypertension and sympathetic activation and, thus, requires longer therapy to elicit a significant change (31) . Because both FXIIa and FVIIa have been associated with increased mortality from cardiovascular events (30, 32, 33) , the observed increase in these clotting factors in association with OSA is another potential mechanism by which OSA may predispose individuals to an increased risk of cardiovascular events. However, the role of CPAP in negating these effects remains unclear.
Fibrinogen (tables 4 and 5)
Fibrinogen is an acute phase protein, which increases during infection or inflammation, and is an independent risk factor for cardiovascular disease (34) (35) (36) . Fibrinogen influences platelet aggregation and hemorheology and, when converted to fibrin, has the ability to form fibrin (18, 19, 25, 26, 37, 38) and D-dimer levels (29, 39) are raised in patients with OSA. Conversely, randomized controlled trials found that fibrinogen levels in patients with OSA were within normal limits (27, 40) . In a study investigating D-dimer (29), a by-product of fibrin degradation (thus, a proxy measure for fibrin), D-dimer levels increased significantly when patients were exposed to hypoxic conditions. This suggests that the patients were in a hypercoagulable state that was mediated, at least partially, by fibrin. However, a more recent study found baseline D-dimer levels to be lower in patients with OSA versus controls (41) . Researchers suggested that because D-dimer is a by-product of fibrin degradation, a decreased level indicates impaired fibrinolysis. Thus, it is unclear what D-dimer levels truly represent in patients with OSA (ie, impaired fibrinolysis or increased fibrin formation). Further investigation is required to clarify this relationship. Wessendorf et al (38) studied 113 patients undergoing rehabilitation after suffering an ischemic stroke. After overnight polysomnography, it was discovered that 42 had mild OSA and 27 had moderate to severe OSA. Furthermore, the level of fibrinogen in these stroke survivors was positively correlated with the number and duration of apneic events (38) . This finding suggests that raised fibrinogen levels may be a pathophysiological link between OSA and stroke. Currently, the evidence describing the effect of CPAP therapy on fibrinogen levels is inconsistent. While some studies have found that fibrinogen levels decrease with CPAP therapy (18, 22) , others have found no change after five nights, four weeks or six months of treatment (20, 23, 27, 42) . The reason for this inconsistency among studies may relate to small sample sizes, varying degrees of sleep apnea severity and associated hypoxemia (hypoxemia is known to increase fibrinogen levels), inconsistent adherance to treatment between studies, variable comorbidities and other methodological issues (43) . Overall, however, despite some inconsistency among studies, the majority have demonstrated an increase in fibrinogen levels in patients with OSA.
impaired fibrinolysis
Impaired fibrinolysis may lead to a hypercoagulable state (44) . Plasminogen activator inhibitor-1 (PAI-1) plays an important role in the regulation of fibrinolytic activity because it inhibits the enzyme tissue plasminogen activator, which is vital to the dissolution of blood clots (45) . Excess PAI-1 has been shown to increase the risk of myocardial infarction (46) (47) (48) (49) . Although several studies have found overall levels of PAI-1 to be increased in patients with OSA, their results are relatively inconsistent (37, 41, 45, (50) (51) (52) (53) . von Kanel et al (50) (51) (52) repeatedly found a positive correlation between patients' apnea hypopnea index (AHI) and PAI-1 levels; however, Zamarron et al (45) , found a negative correlation, despite an overall increase in PAI-1 in patients with OSA versus controls. Two weeks of CPAP therapy was shown to decrease PAI-1 (52) . Overall, the majority of studies have found an increase in PAI-1 in patients with OSA. However, because PAI-1 is only a surrogate measure of fibrinolytic activity, the effects on fibrinolysis and overall coagulability can only be inferred.
c-reactive protein C-reactive protein (CRP) is an acute phase protein and a marker of inflammation. CRP levels have been reported to be elevated in patients with OSA (54, 55) . However, the nature of the relationship between OSA and CRP is uncertain because obesity, a common associated condition in patients with OSA, is also reported to be associated with increased CRP levels (54, 55) . Recently, however, OSA has been linked to increased CRP levels independent of visceral obesity (56) , and CRP levels have also been reported to increase with increasing severity of OSA (57). Lui et al (56) reported that CRP was significantly associated with both AHI (P<0.001) and duration of oxygen saturation <90% (P=0.002), after adjusting for weight and body mass index (56) . Furthermore, treatment of OSA over a six-month period with CPAP was associated with a significant reduction in CRP levels (58, 59) .
In a novel study (60) , researchers showed that CRP increased PAI-1 levels. Previously, there was no evidence suggesting that CRP contributed to clot formation through this mechanism. To date, there has only been one study that examined the relationship among CRP, PAI-1 and OSA (61) . CRP and PAI-1 were found to be raised in patients with OSA and this corresponded with a decrease in tissue plasminogen activator activity, suggesting that CRP, which is generally considered to be an important marker for cardiovascular disease, may also be a marker for increased risk of thrombotic events (61). Hence, there is reasonably strong evidence to suggest that OSA is associated with increased CRP levels, and limited evidence that elevated CRP levels may induce a state of increased coagulability.
tissue factor (table 6) Tissue factor (TF) is a protein that initiates the extrinsic coagulation pathway and the formation of a fibrin clot (62) . TF levels are (63, 64) . However, results from several studies suggest that the increase in TF is not correlated with patients' AHI or OSA severity (51, 52, 63) , and studies investigating the effect of CPAP therapy (52, 63) have yielded inconsistent results. Following these reports, it was determined that TF is correlated with time awake after sleep onset and general sleep inefficiency rather than apneic events (51). This is contrary to the previous hypothesis that TF is released as a result of the hypoxic conditions experienced during sleep apneas (63) . Currently, the relationship between TF and OSA is unclear. Hypoxia has been shown to induce TF production via activation of transcription factor early growth factor-1 (65) . However, it is unclear why the hypoxic conditions experienced by individuals with OSA are not correlated with TF despite an overall increase in TF in this patient population. Further investigation is (table 7) von Willebrand Factor (VWF) is a circulating, procoagulant molecule that mediates platelet adhesion to injured endothelial cells and prevents factor VIII degradation (66) . At this time, there is conflicting evidence regarding the relationship between OSA and VWF -some reports describe no significant difference in VWF levels between controls and patients (27, 52) , while others have found an increase in VWF in patients with OSA (63) . Several reports have demonstrated that VWF levels do not change with CPAP treatment (27, 52, 63) . Thus, similar to TF, VWF may be a marker of sleep fragmentation rather than OSA specifically and, at this time, cannot be characterized as a causal link between OSA and cardiovascular events (51, 52) .
platelet activity (table 8)
Blood platelets are an important component in the maintenance of hemostasis; however, they also contribute to the development of thrombotic clots, which lead to coronary and cerebral ischemia (67).
While some authors found no association between platelet activation and OSA (20, 37) , many others have found platelet activity to be increased in patients with OSA (22, (68) (69) (70) (71) (72) (73) . Platelet aggregation was best correlated with AHI (70), and significantly increased in moderateto-severe OSA versus non-to-mild OSA (74) . The severity of OSA (as measured by the 3% oxygen desaturation index) influenced platelet aggregability to a greater degree than total hypoxic time (72) . A study by Hui et al (70) found that platelet aggregation in patients with OSA decreased significantly after both one-night and three-month CPAP therapy, while control subjects experienced no change. Others have found one month of CPAP therapy to be sufficient to produce an effect (22, 75) . Conversely, a study by Oga et al (72) found 30 days to be inadequate, and only after 90 days of CPAP therapy did they see a statistically significant reduction in platelet aggregability. Overall, the available data suggest a decrease in platelet activation after CPAP treatment in patients with OSA, although the duration of therapy required remains unclear.
silent brain infarction
Magnetic resonance imaging has been used to determine the prevalence of silent brain infarction (SBI) in patients with OSA. Twenty- Yes VWF within the normal laboratory range (ie, P not significant). One month CPAP had no effect on VWF levels (ie, P not significant) five per cent of individuals with moderate-to-severe OSA had magnetic resonance imaging evidence of SBI compared with 7.7% in patients with mild OSA and 6.7% in controls (4). Patients and controls were well matched, and all study participants were free from the major confounding factors (eg, hypertension and smoking). In the moderate-to-severe group, levels of soluble CD40 ligand (sCD40L) and soluble P-selectin -two important markers of platelet activation -were significantly raised in patients with OSA, and fell significantly after three months of CPAP therapy (4) . A subsequent study (68) determined that the levels of sCD40L were correlated with the severity of hypoxia experienced and, again, improved with CPAP. These data suggest that OSA is associated with an increased prevalence of SBI, and this is associated with (and possibly mediated by) increased platelet activation (4).
catecholamines (table 9)
The exact cause of the increased platelet activation in patients with OSA remains unclear. One possible explanation is catecholamineinduced platelet activation (76) . This is evidenced by the fact that patients with OSA exhibit increased sympathetic activation, due to repeated episodes of nocturnal oxyhemoglobin desaturation, which leads to the release of circulating catecholamines (77, 78) . Patients with OSA have increased levels of urinary noradrenaline, and this increase is associated with the degree of oxygen desaturation experienced during sleep (14, 78) . Furthermore, most studies have concluded that CPAP therapy decreases both urinary noradrenaline and adrenaline through increased clearance from the circulation (77) , which supports the suggestion that OSA is an independent factor mediating catecholamine release (78,79). Only Comondore et al (42) found that four months of CPAP therapy had no effect on urinary noradrenaline. In a study of noradrenaline-activated platelets, it was found that acetylsalicylic acid is not entirely effective as an antithrombotic agent (76) . The combined effects of acetylsalicylic acid and CPAP therapy may be more effective, although this remains to be studied in this patient population. Platelet activation and its effects on coagulation may, in part, explain why patients with OSA are at an increased risk for both fatal and nonfatal cardiovascular accidents, and why CPAP therapy effectively reduces the incidence of cardiovascular events (6).
venous thromboembolism
Relatively few studies have examined the association between coagulation-related clinical events such as venous thromboembolism (VTE) and pulmonary embolism (PE). Existing studies are hampered by small sample size and a lack of adequate control groups (80) (81) (82) (83) (84) . Recently, Epstein et al (82) reported that patients with PE exhibited a higher prevalence of snoring than those without PE (75% versus 50%; OR 2.91; P=0.001). They also reported that patients with PE had an increased risk of OSA as determined using the Berlin Questionnaire (65% versus 36%; OR 3.25 [P<0.001]) compared with those without PE. However, the latter study was limited by the failure to objectively confirm or refute OSA and snoring using overnight polysomnography. Furthermore, the study did not examine whether there was a difference in laboratory-based coagulability testing between those with high probability for OSA and PE versus those with low probability for OSA and PE (82) . A recent retrospective analysis (83) revealed a prevalence of objectively documented OSA of 15.5% among patients with VTE -a higher prevalence than is reported for the general population -but did not adjust for confounding variables. Hence, although it is tantalizing to speculate that patients with OSA are at increased risk of VTE because of a hypercoagulable state, there is relatively little published evidence to support that contention. In particular, there is a need for adequately powered clinical studies involving well-matched control groups that address potential confounding variables to answer this question.
Whole blood coagulability (table 10)
As demonstrated above, many studies have attempted to determine the relationship between OSA and coagulation. However, only two studies to date have examined whole blood coagulability and OSAone animal model of OSA (85) and one study involving human subjects (86) . Both studies used thromboelastography, which is a global assay of hemostatic function. Thromboelastography is able to measure various aspects of coagulation including time before initial fibrin formation, rapidity of clot formation and maximum clot strength. This provides a more complete picture of coagulation because all blood components are involved.
In anesthetized rats, Othman et al (85) found that a hypercoagulable state was induced by repeated inspiratory occlusions. Guardiola et al (86) determined that untreated patients with OSA were in a state of increased coagulability compared with CPAP-treated patients. However, unlike previous studies that reported significant reductions in plasma fibrinogen levels after only one night of CPAP therapy (37, 69) , and alluded to a potential decrease in overall coagulability, Guardiola et al (86) did not find a change in whole blood coagulability after a single night of CPAP therapy. This suggests that while hematological factors may change rapidly, chronic therapy may be required to realize any effects on overall hemostasis. Table 11 summarizes the major findings from the present comprehensive literature review. The available data suggest that patients with OSA are in a procoagulant state, but the relationships between OSA and individual clotting factors are uncertain. Future research will require the use of randomized controlled trials with sufficient statistical power and careful attention to treatment efficacy and adherence, to determine the relationship between individual procoagulant factors and OSA. Given the high degree of cardiovascular morbidity and mortality associated with OSA, the hypercoagulable state induced by OSA clearly warrants further study. In particular, the potential for 
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